LLY

757.36

+3.2%↑

JNJ

151.29

+1.18%↑

UNH

291.24

+6.59%↑

ABBV

183.96

+1.27%↑

NVO

64.34

-2.56%↓

LLY

757.36

+3.2%↑

JNJ

151.29

+1.18%↑

UNH

291.24

+6.59%↑

ABBV

183.96

+1.27%↑

NVO

64.34

-2.56%↓

LLY

757.36

+3.2%↑

JNJ

151.29

+1.18%↑

UNH

291.24

+6.59%↑

ABBV

183.96

+1.27%↑

NVO

64.34

-2.56%↓

LLY

757.36

+3.2%↑

JNJ

151.29

+1.18%↑

UNH

291.24

+6.59%↑

ABBV

183.96

+1.27%↑

NVO

64.34

-2.56%↓

LLY

757.36

+3.2%↑

JNJ

151.29

+1.18%↑

UNH

291.24

+6.59%↑

ABBV

183.96

+1.27%↑

NVO

64.34

-2.56%↓

Kodu・Aktsiate loetelu・BioNTech SE ADR

BioNTech SE ADR

Suletud

SektorTervishoid

92.77 0.5

Osta Müü

Ülevaade

Aktsiahinna muutus

24h

Praegune

Min

91.14

Max

93.03

Põhinäitajad
By Trading Economics
Sissetulek	-717M -416M
Müük	-1B 183M
Aktsiakasum	-1.821
Kasumimarginaal	-227.462
Töötajad	6,772
EBITDA	253M 464M

Soovitused
By TipRanks
Soovitused	Tugev "osta" hinnang
12 kuu keskmine prognoos	+51.41% upside

Dividendid
By Dow Jones
Järgmine tulemuste avaldamine	4. aug 2025

Turustatistika
By TradingEconomics
Turukapital	-1.8B 23B
Eelmine avamishind	92.27
Eelmine sulgemishind	92.77

Uudiste sentiment

By Acuity

43%

57%

150 / 382 Pingereas Healthcare

Tehniline skoor

By Trading Central

Kindlus

Very Strong Bearish Evidence

92.4 / 103.5 Toetus ja vastupanu

BioNTech SE ADR Graafik

Mineviku tootlus ei ole usaldusväärne näitaja tulevaste tulemuste kohta.

Seotud uudised

4. veebr 2025, 18:52 UTC

Suurimad hinnamuutused turgudel

Psychedelic Drug Stocks Up, Vaccine Shares Down After Senate Committee Advances RFK Jr.

15. nov 2024, 10:28 UTC

Suurimad hinnamuutused turgudel

European Vaccine Makers Under Pressure After Trump Picks RFK Jr to Lead Health Department

5. mai 2025, 15:13 UTC

Market Talk

Tulu

Narrower Guidelines for Covid-19 Booster Wouldn't Limit BioNTech's Customer Base Much -- Market Talk

15. nov 2024, 11:14 UTC

Market Talk

U.S. Vaccine Stocks Fall After Trump Picks Vaccine Skeptic RFK Jr as Health Department Head-- Market Talk

15. nov 2024, 10:34 UTC

Market Talk

Vaccine Sector Sell-Off Looks Overdone -- Market Talk

5. aug 2024, 10:02 UTC

Tulu

BioNTech Sees 2024 R&D Expenses EUR2.4B-EUR2.6B >BNTX

5. aug 2024, 10:01 UTC

Tulu

BioNTech Backs 2024 View of Rev EUR2.5B-EUR3.1B >BNTX

5. aug 2024, 10:01 UTC

Tulu

BioNTech: Invested EUR525.6M, or About 90% of 2Q R&D Spend, in Non-Covid-19 Related Activities >BNTX

5. aug 2024, 10:00 UTC

Tulu

BioNTech 2Q-End Cash, Equivalents, Security Investments EUR18.5 Billion >BNTX

5. aug 2024, 09:59 UTC

Tulu

BioNTech 2Q Loss EUR807.8M >BNTX

5. aug 2024, 09:59 UTC

Tulu

BioNTech 2Q Loss/Shr EUR3.36 >BNTX

5. aug 2024, 09:59 UTC

Tulu

BioNTech 2Q Rev EUR128.7M >BNTX

Võrdlus sarnastega

Hinnamuutus

BioNTech SE ADR Prognoos

Hinnasiht

By TipRanks

51.41% tõus

12 kuu keskmine prognoos

Keskmine 139.81 USD 51.41%

Kõrge 171 USD

Madal 110 USD

Põhineb 18 Wall Streeti analüütiku instrumendi BioNTech SE ADR 12 kuu hinnasihil - viimase 3 kuu andmed.

Hinnangu Konsensus

By TipRanks

Tugev "osta" hinnang

18 ratings

Osta

Hoia

Müü

Põhineb 18 analüütiku instrumendi BioNTech SE ADR aktsia reitingul - viimase 3 kuu andmed.

Tehniline skoor

By Trading Central

92.4 / 103.5Toetus ja vastupanu

Recent bearish events outweigh bullish events.

Sentiment

By Acuity

150 / 382 Pingereas Tervishoid

Finantsandmed

Müügi- ja halduskulud

Tegevuskulud

Maksueelne kasum

Müük

Müügikulu

Brutokasum müügist

Intressikulud võla pealt

EBITDA

Ärikasum

Ettevõttest BioNTech SE ADR

BioNTech SE, a biotechnology company, develops and commercializes immunotherapies for cancer and other infectious diseases. The company is developing FixVac product candidates, including BNT111, which is in Phase II clinical trial for advance melanoma; BNT112 that is in Phase I/IIa clinical trial for prostate cancer; BNT113, which is in Phase II clinical trial to treat HPV 16+ head and neck cancers; BNT114 to treat triple negative breast cancer; BNT115, which is in Phase I clinical trial in ovarian cancer; and BNT116, which is in Phase I clinical trial for non-small cell lung cancer. It develops BNT122, which is in Phase II clinical trial for first-line melanoma and in Phase I clinical trial to treat multiple solid tumors; BNT131 that is in Phase I clinical trial for multiple solid tumors; BNT141 and BNT142 that are in Phase I clinical trial to treat multiple solid tumors; BNT151, BNT152, and BNT153 to treat solid tumors; BNT211 to treat multiple solid tumors, and BNT221 for pancreatic and other cancers; BNT311 which are in Phase II clinical trial to treat metastatic non-small cell lung cancer and Phase I/II clinical trial to treat multiple solid tumors; and BNT312, which is in Phase 2 clinical trial to treat multiple solid tumors, as well as ONC-392, which is in Phase III clinical trial to treat ovarian cancer and Phase I/II clinical trial to treat multiple solid tumors. It develops BNT321, an IgG1 monoclonal antibody in Phase I clinical trial for pancreatic cancer; BNT411, a small molecule immunomodulator product candidate in Phase I clinical trial for solid tumors; BNT322, which is in Phase I/Ib clinical trial for multiple solid tumors; and prophylactic vaccine for shingles, malaria, tuberculosis, HSV-2, and other infectious diseases. It has collaborations with Genentech, Inc.; Sanofi S.A.; Genmab A/S; Pfizer Inc.; Shanghai Fosun Pharmaceutical (Group) Co., Ltd; and Ryvu Therapeutics S.A, as well as strategic partnership the Coalition for Epidemic Preparedness Innovations (CEPI) to strengthen africa's mrna vac